We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

113 hedge funds and large institutions have $1.54B invested in C4 Therapeutics in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 20 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 20

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

28% more capital invested

Capital invested by funds: $1.21B → $1.54B (+$334M)

6% more funds holding

Funds holding: 107 → 113 (+6)

2.76% less ownership

Funds ownership: 73.95% → 71.19% (-2.8%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
113
Holders Change
+6
Holders Change %
+5.61%
% of All Funds
1.98%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
19
Increased
53
Reduced
20
Closed
12
Calls
$4.63M
Puts
–
Net Calls
+$4.63M
Net Calls Change
+$2.71M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$22.8M
2
BlackRock
BlackRock
New York
+$22.5M
3
DCM
Driehaus Capital Management
Illinois
+$18.6M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.7M
5
RI
RTW Investments
New York
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$13.4M
2
MS
Maven Securities
Jersey
-$8.96M
3
LCM
Laurion Capital Management
New York
-$6.55M
4
MS
Mizuho Securities
Japan
-$6.41M
5
PCM
Pinz Capital Management
New York
-$6.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$15.4M +$4.58M +106,944 +53%
Morgan Stanley
27
Morgan Stanley
New York
$13M +$596K +13,908 +5%
Millennium Management
28
Millennium Management
New York
$12.8M -$4.15M -96,975 -25%
Goldman Sachs
29
Goldman Sachs
New York
$11.8M +$1.41M +33,001 +14%
Charles Schwab
30
Charles Schwab
California
$11.6M +$5.13M +119,858 +85%
EC
31
EcoR1 Capital
California
$8.94M – – –
Point72 Asset Management
32
Point72 Asset Management
Connecticut
$8.94M +$1.47M +34,400 +21%
Alyeska Investment Group
33
Alyeska Investment Group
Illinois
$5.58M +$5.35M +125,000 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$5.03M +$1.2M +28,053 +33%
Voloridge Investment Management
35
Voloridge Investment Management
Florida
$4.71M +$387K +9,036 +9%
TD Asset Management
36
TD Asset Management
Ontario, Canada
$4.46M +$167K +3,900 +4%
First Trust Advisors
37
First Trust Advisors
Illinois
$3.88M +$2.77M +64,688 +291%
AllianceBernstein
38
AllianceBernstein
Tennessee
$3.63M +$853K +19,915 +32%
Citigroup
39
Citigroup
New York
$2.98M -$374K -8,728 -12%
SSA
40
Schonfeld Strategic Advisors
New York
$2.78M +$2.67M +62,253 New
Rafferty Asset Management
41
Rafferty Asset Management
New York
$2.64M +$438K +10,218 +21%
Federated Hermes
42
Federated Hermes
Pennsylvania
$2.62M +$2.51M +58,612 New
JP Morgan Chase
43
JP Morgan Chase
New York
$2.45M +$1.64M +38,293 +232%
EHI
44
Eagle Health Investments
Connecticut
$2.11M – – –
BG
45
Bellevue Group
Switzerland
$2.11M +$694K +16,200 +52%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$1.99M – – –
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$1.94M +$852K +19,888 +85%
Citadel Advisors
48
Citadel Advisors
Florida
$1.8M -$3.02M -70,443 -64%
PAWC
49
P.A.W. Capital
Connecticut
$1.79M -$428K -10,000 -20%
JF
50
Jump Financial
Illinois
$1.77M +$1.7M +39,700 New
1
2
3 4 5

CCCC Hedge Fund Activity: Q3 2021 in Review

113 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2021, worth a combined $1.54B — up 28% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CCCC positions and 12 closed out — a net gain of 7 holders — while 53 added to existing stakes and 20 trimmed.

The largest buyer was Vanguard Group, adding an estimated $22.8M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $13.4M sold.

  • 113 institutional investors held C4 Therapeutics (CCCC) as of Q3 2021, up from 107 in Q2 2021.
  • Funds reported $1.54B of C4 Therapeutics stock for Q3 2021, up 28% quarter-over-quarter.
  • 19 funds opened new C4 Therapeutics positions in Q3 2021 and 12 closed out, a net change of +7 holders.
  • The largest C4 Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $22.8M added.
  • The largest C4 Therapeutics seller in Q3 2021 was Cormorant Asset Management, an estimated $13.4M sold.

Based on aggregated 13F filings for Q3 2021.